NIHR Oxford Biomedical Research Centre

Enabling translational research through partnership

MENUMENU
  • About
    • About the NIHR Oxford Biomedical Research Centre
    • A Guide to What We Do
    • Activities during COVID-19
    • Strategic Partnership Board
    • Steering Committee
    • Promoting Equality, Diversity and Inclusion in Research
    • Current Vacancies
    • Contact Us
    • Stay in Touch
  • Research
        • OUR 20 RESEARCH THEMES

        • Antimicrobial Resistance and Modernising Microbiology
        • Cardiovascular
        • Clinical Informatics and Big Data
        • Diabetes and Metabolism
        • Gastroenterology and Mucosal Immunity
        • Genomic Medicine
        • Haematology and Stem Cells
        • Imaging
        • Molecular Diagnostics
        • Multi-Modal Cancer Therapies
        • Multi-Morbidity and Long-Term Conditions
        • Musculoskeletal
        • Neurological Conditions
        • Obesity, Diet and Lifestyle
        • Partnerships for Health, Wealth and Innovation
        • Respiratory
        • Stroke and Vascular Dementia
        • Surgical Innovation and Evaluation
        • Technology and Digital Health
        • Vaccines for Emerging and Endemic Diseases
        • Oxford Biomedical Research Centre activities during COVID-19
  • Patient & Public Involvement
    • About Patient and Public Involvement
      • Our Work with Patients and the Public
      • Learn More About Our Research
      • Patient Involvement Blog
      • External Links
    • For Patients, Carers and the Public
      • Current Listings for Involvement
      • REGISTER INTEREST
      • Patient and Public Involvement Workshops
    • PPI Resources for Researchers
      • PPI Strategy
      • A Researcher’s Guide to PPI
      • PPI Resources for Researchers
      • PPI Briefing Notes
      • PPI Case Studies
      • PPI Advisory Group
      • PPI Events for Researchers
      • Post a PPI Listing
      • Public Engagement for Researchers
      • Public Engagement Case Studies
  • Training Hub
    • Training Hub
    • Fellowships
    • Funding Opportunities
    • Clinical Researchers and Scientists
    • Nurses, Midwives and Allied Health Professionals
    • Next Generation Leaders Programme
    • Useful Links
    • Training and Education Resources
    • Upcoming Training Events & Courses
  • Industry
    • Collaborate with Oxford BRC
    • What Can We Do For Your Organisation?
    • Who Do We Work With?
    • IP and Licensing
    • Contacts for Industry
  • Videos
  • News
  • Events

News

You are here: Home > Multi-Modal Cancer Therapies > New clinical trial aims to tackle bowel cancer

New clinical trial aims to tackle bowel cancer

9 February 2018 · Listed under Multi-Modal Cancer Therapies

Oxford University Hospitals has started a clinical trial which combines the use of immunotherapy with a protein-inhibiting drug for use with difficult-to-treat bowel cancer.

Immunotherapy combined with checkpoint inhibitor drugs has been used successfully as treatment for  several cancers, including melanoma and lung cancer, but until now has not worked so effectively on bowel cancer.

This study will test the combination of immunotherapy with binimetinib, which inhibits the protein MEK (mitogen-activated protein kinase kinase), which is often activated in bowel cancer.

Prof Mark Middleton, Head of the Department of Oncology at the University of Oxford, said: “Immunotherapy is a very exciting new treatment, but it only works against some types of cancer. Fresh approaches are needed to try to make more cancers sensitive to treatment, so it is great to be able to offer this type of trial to patients in Oxford.”

A quarter of bowel cancers have a mutation in a gene called KRAS, and these are particularly difficult to treat because some standard drugs for bowel cancer are ineffective in this situation. When RAS genes, such as KRAS, are mutated, the MEK pathway is overactive. Studies have shown that turning this pathway off can make tumours more susceptible to immunotherapy.

The Early Phase Clinical Trials Unit at the Churchill Hospital is part of the Experimental Cancer Medicines Centre Network, which is funded by the National Institute for Health Research (NIHR) and Cancer Research UK. Professor Middleton’s work is supported by the NIHR Oxford Biomedical Research Centre (BRC), where he is the Co-theme Lead for Multi-modal Cancer Therapies.

Binimetinib is an MEK-inhibitor developed by Array Biopharma to treat a number of cancers.

← Top Oxford cancer specialist retires from clinical work
Health minister visits Oxford BRC →

News

  • COVID-19 ‘matching service’ increased public involvement in research, HRA finds 20 January 2021
  • Classification system uncovers new information about ovarian cancers 18 January 2021
  • Ancient gene mutation found to cause rare hereditary condition 18 January 2021
See full news archive

News Categories

Month Archives

Subscribe to the Oxford BRC Newsletter

Keep informed about the work of the Oxford BRC by subscribing to our Mailchimp e-newsletter. It is produced bimonthly and delivers news and information about upcoming events straight to your inbox.

Subscribe Now

Oxford BRC on Social Media

  • Facebook
  • Twitter
  • YouTube

Feedback

We’d love to hear your feedback. Please contact us at obrcenquiries@ouh.nhs.uk

  • Sitemap
  • Data Control and Privacy
  • Accessibility
  • Our Partners
  • Disclaimer
  • Contact

Copyright © 2021 NIHR Oxford Biomedical Research Centre

Cookies

This site uses cookies See our data control and privacy page